|drug3976||morning Yoga-based breathing support Wiki||1.00|
|drug4049||pre_dinner Yoga-based breathing support Wiki||1.00|
|D011618||Psychotic Disorders NIH||0.41|
|D001523||Mental Disorders NIH||0.20|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
COronaVIrus Disease or Severe Acute Respiratory Syndrome -CoV-2 or COVID-19, mortality occurs mainly from immunological behavior or by suicide after healing . In both cases, the causal link is coronavirus within the host response. The rationale of use of deep yoga breathing as adjuvant treatment to COVID-19 disease , is linked to the mechanical action to stimulate the vagus nerve through scalene and sternocleidomastoid muscles function of which the continuity of action bring to modulate upto suppress, the inflammatory reflex and pro-inflammatory cytokines overproduction and contextual lowering of the sympathetic stress response as a first cause of sleep and late mental disorders which can increase the annual suicide rate. An easily breathing medical Yoga protocol has been developed to test a cost-effective care provision, training, contact tracing and mass efficacy testing.
Description: COVID-19's Patients mortality all cause: incidence proportion.Measure: Mortality Time: 12 months.
Description: COVID-19's Patients suicide: incidence proportion.Measure: Mortality-suicide Time: 12 months.
Description: In-hospital COVID-19's Patients oxygen invasive ventilation or high flow oxygen devices :incidence proportion of Brescia COVID-19 respiratory Severity Scale Index (Levels 0-3 worse outcome) cutoff Level ≥ 2 -Measure: Incidence of hospitalization for respiratory failure of COVID-19's Patients- Time: 1 months.
Description: Homecare interventions for anxiety and depression requiring drugs treatment: incidence proportion.Measure: Incidence of al home professional psychiatric-psychological interventions for mental disorder. Time: 12 months.
Description: Scoring system for depression and anxiety requiring drugs treatment: incidence proportion of BDI-II aggregate components score 0- 63 ( worse outcome) , cutoff > 29.Measure: Incidence of mental disorder: Beck Depression Inventory-Second Edition (BDI-II). Time: 12 months.
Description: Scoring system for sleep disorders requiring drugs treatment: incidence proportion of aggregate PSQI score 0-21 (worse outcome) , cutoff > 8.Measure: Incidence od spleep disorder:Pittsburgh Sleep Quality Index (PSQI). Time: 12 months.
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports